Modelling acute tolerance to the EEG effect of two benzodiazepines

British Journal of Clinical Pharmacology

Volumn 57, Issue 2, 2004, Pages 153-161

  Ihmsen, Harald ^a,b   Albrecht, Sven ^a   Hering, Werner ^a   Schüttler, Jürgen ^a   Schwilden, Helmut ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Benzodiazepines; Electroencephalogram; Pharmacodynamics; Tolerance

Indexed keywords

3 (5 DIPROPYLAMINOMETHYL 1,2,4 OXADIAZOL 3 YL) 8 FLUORO 5,6 DIHYDRO 5 METHYL 4H IMIDAZO[1,5 A][1,4]BENZODIAZEPIN 6 ONE; BENZODIAZEPINE DERIVATIVE; DRUG METABOLITE; MIDAZOLAM; RO 48 679; UNCLASSIFIED DRUG;

ADULT; AGED; ARTERIAL BLOOD; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPETITIVE ABILITY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFECT; DRUG METABOLISM; DRUG POTENTIATION; DRUG TARGETING; DRUG TOLERANCE; ELECTROENCEPHALOGRAM; EXPERIMENTAL MODEL; FOLLOW UP; HUMAN; HYPNOSIS; INFUSION; INTERMETHOD COMPARISON; MALE; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPECTRUM;

ADULT; AGED; AGED, 80 AND OVER; BENZODIAZEPINES; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG RESISTANCE; ELECTROENCEPHALOGRAPHY; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDAZOLAM;

EID: 1242306690     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01964.x     Document Type: Article

References (25)

1. Coldwell SE, Kaufman E, Milgrom P et al. Acute tolerance and reversal of the motor control effects of midazolam. Pharmacol Biochem Behav 1998; 59: 537-45.
2. Greenblatt DJ, Shader RI. Dependence, tolerance, and addiction to benzodiazepines: clinical and pharmacokinetic considerations. Drug Metab Rev 1978; 8: 13-28.
3. Kroboth PD, Smith RB, Erb RJ. Tolerance to alprazolam after intravenous bolus and continuous infusion: psychomotor and EEG effects. Clin Pharmacol Ther 1988; 43: 270-7.
4. Rosen DA, Rosen KR. Midazolam for sedation in the paediatric intensive care unit. Intensive Care Med 1991; 17: S15-S19.
5. Albrecht S, Ihmsen H, Hering W et al. The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. Clin Pharmacol Ther 1999; 65: 630-9.
6. Dingemanse J, Haussler J, Hering W et al. Pharmacokinetic- pharmacodynamic modelling of the EEG effects of Ro 48-6791, a new short-acting benzodiazepine, in young and elderly subjects. Br J Anaesth 1997; 79: 567-74.
7. Holford NH, Sheiner LB. Kinetics of pharmacologic response. Pharmacol Ther 1982; 16: 143-66.
8. Al-Khudhairi D, Askitopoulou H, Whitwam JG. Acute 'tolerance' to the central respiratory effects of midazolam in the dog. Br J Anaesth 1982; 54: 953-8.
9. Hudson RJ, Stanski DR, Saidman LJ, Meathe E. A model for studying depth of anesthesia and acute tolerance to thiopental. Anesthesiology 1983; 59: 301-8.
10. Fattinger K, Verotta D, Benowitz NL. Pharmacodynamics of acute tolerance to multiple nicotinic effects in humans. J Pharmacol Exp Ther 1997; 281: 1238-46.
11. Porchet HC, Benowitz NL, Sheiner LB. Pharmacodynamic model of tolerance: application to nicotine. J Pharmacol Exp Ther 1988; 244: 231-6.
12. Ouellet DM, Pollack GM. A pharmacokinetic-pharmacodynamic model of tolerance to morphine analgesia during infusion in rats. J Pharmacokinet Biopharm 1995; 23: 531-49.
13. Mandema JW, Tuk B, van Steveninck AL, Breimer DD, Cohen AF, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther 1992; 51: 715-28.
14. Tuk B, van Oostenbruggen MF, Herben VM, Mandema JW, Danhof M. Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam. J Pharmacol Exp Ther 1999; 289: 1067-74.
15. Johnson TN, Rostami-Hodjegan A, Goddard JM, Tanner MS, Tucker GT. Contribution of midazolam and its 1-hydroxy metabolite to preoperative sedation in children: a pharmacokinetic-pharmacodynamic analysis. Br J Anaesth 2002; 89: 428-37.
16. Kroboth PD, Bertz RJ, Smith RB. Acute tolerance to triazolam during continuous and step infusions: estimation of the effect offset rate constant. J Pharmacol Exp Ther 1993; 264: 1047-55.
17. Somma J, Donner A, Zomorodi K et al. Population pharmacodynamics of midazolam administered by target controlled infusion in SICU patients after CABG surgery. Anesthesiology 1998; 89: 1430-43.
18. Fiset P, Lemmens HL, Egan TE, Shafer SL, Stanski DR. Pharmacodynamic modeling of the electroencephalographic effects of flumazenil in healthy volunteers sedated with midazolam. Clin Pharmacol Ther 1995; 58: 567-82.
19. Shafer A. Complications of sedation with midazolam in the intensive care unit and a comparison with other sedative regimens. Crit Care Med 1998; 26: 947-56.
20. Shelly MP, Sultan MA, Bodenham A, Park GR. Midazolam infusions in critically ill patients. Eur J Anaesthesiol 1991; 8: 21-7.
21. Schwilden H, Stoeckel H, Lauven PM. Dosisfindung von Midazolam und Wirkkontrolle über EEG. In: Midazolam in der Anästhesiologie, ed Götz E. Basel: Editions Roche, 1984; 41-7.
22. Gardmark M, Brynne L, Hammarlund-Udenaes M, Karlsson MO. Interchangeability and predictive performance of empirical tolerance models. Clin Pharmacokinet 1999; 36: 145-67.
23. Bateson AN. Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal. Curr Pharm Des 2002; 8: 5-21.
24. Rosenberg HC, Chiu TH. Tolerance during chronic benzodiazepine treatment associated with decreased receptor binding. Eur J Pharmacol 1981; 70: 453-60.
25. Tietz EI, Chiu TH, Rosenberg HC. Regional GABA/benzodiazepine receptor/chloride channel coupling after acute and chronic benzodiazepine treatment. Eur J Pharmacol 1989; 167: 57-65.